NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Longer-Lasting eye injection could cut treatment visits for macular disease
Disease control Not yet recruitingThis study looks at whether switching to a higher-dose eye injection called aflibercept 8 mg can allow people with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DME) to go longer between treatments. It follows adults in Portugal who have already …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Grupo de Estudos da Retina • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Eye drops could replace needle injections for wet AMD
Disease control Not yet recruitingThis Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: SCAI Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could herbal pills cut eye injections for wet AMD? new trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC